Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility.
RR Kabel shares jump 10% as Q1 PAT surges 129% YoY, Ebitda doubles
RR Kabel reported a strong June-quarter performance, with profit after tax surging 129% year-on-year and Ebitda nearly doubling, driven by robust growth in its Wires
July 28, 2026